Dyne Therapeutics, Inc. announced promising preclinical data for their therapeutic candidate, DYNE-302, which shows potential for functional improvement in facioscapulohumeral muscular dystrophy ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced ...

Dyne Therapeutics officer sells shares worth $1,949 View all comments (0) 0 Latest comments Post Comment Guidelines Trade With A Regulated Broker Indices Commodities Bonds Stocks US 30 42,759.00 ...

On Tuesday, Dyne Therapeutics Inc. (NASDAQ:DYN) announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to exon ...

Dyne Therapeutics, Inc. announced the appointment of Erick J. Lucera as its new Chief Financial Officer, effective March 31, 2025. Lucera brings over 30 years of experience in the life sciences ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Dyne Therapeutics (DYN – Research Report), boosting the price target to $55.00. Andrew Fein has given his Buy rating due to a ...

Health and Human Services Secretary Robert F. Kennedy Jr. said on Thursday that the U.S. drugs regulator would look for ways ...

WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with ...

Dyne Therapeutics, Inc. develops treatments for muscle diseases using its FORCE platform, with promising candidates DYNE-101 and DYNE-251 targeting DM1 and DMD, respectively. DYNE-251 shows ...

WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with ...